Search Results - Matthew Hellmann
- Showing 1 - 6 results of 6
-
1
459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC by Matthew Hellmann, Ying Cheng, Toshiaki Takahashi, Gilberto de Castro, M Catherine Pietanza, James Chih-Hsin Yang, Byoung Cho, Rosalyn Juergens, Mustafa Erman, Jessica Bauman, Paul Schwarzenberger, Pingye Zhang
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
2
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma by Jiajia Zhang, Patrick Forde, Taha Merghoub, Julie Brahmer, Matthew Hellmann, Kristen Marrone, Janis Taube, Boyang Zhang, Hongkai Ji, Zhicheng Ji, Justina Caushi, Andrew Pardoll, Kellie Smith, Giacomo Oliveira, Srinivasan Yegnasubramanian, Catherine Wu
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
3
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status by Mark Awad, Mizuki Nishino, Mehmet Altan, Biagio Ricciuti, Fangxin Hong, Matthew Hellmann, John V Heymach, Joao V Alessi, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Published in Journal for ImmunoTherapy of Cancer (2020-10-01)Get full text
Article -
4
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) by Enriqueta Felip, Jianda Yuan, Lawrence Fong, Charu Aggarwal, Razvan Cristescu, Myung-Ju Ahn, Alexandra Snyder, Matthew Hellmann, Roy Herbst, Martin Gutierrez, Edward Garon, Jong-Seok Lee, Julie Kobie, Matthew Gubens, Daniel Shao Weng Tan, Joanne WY Chiu, James Chih-Hsin Yang, Giovanna Finocchiaro, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, John Palcza
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
5
524 Tim-4+ resident macrophages impair anti-tumor immunity in the serous body cavities By sequestering viable and cytotoxic CD8+ T cells expressing high levels of phosphatidylserin... by Michael Green, Dmitriy Zamarin, Katherine Panageas, Taha Merghoub, Weiping Zou, Cailian Liu, Jedd Wolchok, Matthew Hellmann, Joseph Chan, Hongyu Shi, Hira Rizvi, Jessica Waninger, Aditi Gupta, Nicholas Ceglia, Viola Allaj, Giulia Zago, Nisarg Shah, Sai Sharma, Marissa Mattar, Yonina Bykov, Corrin Wohlhieter, Fathema Uddin, Inna Khodos, Angel Qin, Vinod Balachandran, Sohrab Shah, Andrew McPherson, Jason Lewis, Justin Perry, Elisa de Stanchina, Triparna Sen, John Poirier, Charles Rudin
Published in Journal for ImmunoTherapy of Cancer (2020-11-01)Article -
6
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of C... by Chen Zhao, Li Chen, Albrecht Stenzinger, Yali Li, Naiyer Rizvi, Jeff Allen, Matthew Hellmann, Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary, Wangjuh (Sting) Chen, Jen-Hao Cheng, Dinesh Cyanam, Jennifer S Dickey, Vikas Gupta, Elena Helman, Joerg Maas, Arnaud Papin, Rajesh Patidar, Katie J Quinn, Hongseok Tae, Christine Ward, Mingchao Xie, Ahmet Zehir, Manfred Dietel, Mark Stewart
Published in Journal for ImmunoTherapy of Cancer (2020-05-01)Get full text
Article
